Details

Autor(en) / Beteiligte

• Huinen, Zowi R
• Huijbers, Elisabeth J M
• van Beijnum, Judy R
• Nowak-Sliwinska, Patrycja
• Griffioen, Arjan W

Titel

Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes

Ist Teil von

• Nature reviews. Clinical oncology, 2021-08, Vol.18 (8), p.527-540

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• Immune checkpoint inhibitors have revolutionized medical oncology, although currently only a subset of patients has a response to such treatment. A compelling body of evidence indicates that anti-angiogenic therapy has the capacity to ameliorate antitumour immunity owing to the inhibition of various immunosuppressive features of angiogenesis. Hence, combinations of anti-angiogenic agents and immunotherapy are currently being tested in >90 clinical trials and 5 such combinations have been approved by the FDA in the past few years. In this Perspective, we describe how the angiogenesis-induced endothelial immune cell barrier hampers antitumour immunity and the role of endothelial cell anergy as the vascular counterpart of immune checkpoints. We review the antitumour immunity-promoting effects of anti-angiogenic agents and provide an update on the current clinical successes achieved when these agents are combined with immune checkpoint inhibitors. Finally, we propose that anti-angiogenic agents are immunotherapies - and vice versa - and discuss future research priorities.